Nomogram for bretylium dosing in renal impairment

Area of Science:

• Pharmacology
• Nephrology
• Critical Care Medicine

Background:

• Bretylium (Bretylol) is an antiarrhythmic agent used for life-threatening ventricular arrhythmias.
• Its delayed onset, potential for hypotension, and increased ventricular irritability necessitate cautious use, particularly in renal impairment.

Purpose of the Study:

• To investigate the impact of diminished renal function on bretylium pharmacokinetics.
• To develop a dosage adjustment strategy for patients with renal impairment.

Main Methods:

• Analysis of bretylium plasma concentrations (Cmax) and clearance in relation to renal function.
• Development of a nomogram correlating total body clearance with renal function.

Main Results:

• Normalized maximum plasma concentration (Cmax) of bretylium significantly increases with declining renal function.
• Renal and total body clearance of bretylium are substantially reduced in patients with renal insufficiency.

Conclusions:

• Dosage adjustments for bretylium are essential in patients with renal impairment to prevent toxicity.
• The developed nomogram provides an effective tool for adjusting bretylium dosage based on renal function.